medigraphic.com
Instituto Nacional de Salud Pública

2022, Number 1

<< Back Next >>

salud publica mex 2022; 64 (1)

Aflatoxin levels and prevalence of TP53 aflatoxin-mutations in hepatocellular carcinomas in Mexico

Lino-Silva LS, Lajous M, Brochier M, Santiago-Ruiz L, Melchor-Ruan J, Xie Y, Wang M, Wu D, Higson H, Jones K, Romero-Martínez M, Villalpando S, Mohar A, Smith JW, Alvarez CS, McGlynn KA, Dean M, Groopman J

Language: English
References: 16
Page: 35-40
PDF size: 301.43 Kb.


ABSTRACT

Objective. To determine the exposure to aflatoxin B1 (AFB1) in southern Mexico and the presence of the aflatoxin signature mutation in hepatocellular carcinoma (HCC) tissue from patients from a cancer referral center. Materials and methods. We estimated the prevalence and distribution of AFB1 in a representative sample of 100 women and men from Chiapas using the National Health and Nutrition Survey 2018-19. We also examined the presence of the aflatoxin signature mutation in codon 249 (R249S), and other relevant mutations of the TP53 gene in HCC tissue blocks from 24 women and 26 men treated in a national cancer referral center. Results. The prevalence of AFB1 in serum samples was 85.5% (95%CI 72.1-93.1) and the median AFB1 was 0.117 pg/µL (IQR, 0.050–0.350). We detected TP53 R249S in three of the 50 HCCs (6.0%) and observed four other G›T transversions potentially induced by AFB1. Conclusion. Our analysis provides evidence that AFB1 may have a relevant role on HCC etiology in Mexico.


REFERENCES

  1. Global Burden of Disease Collaborative Network. GBD Results Tool [Internet]. GHdx, 2019 [cited October 26, 2021]. Available from: https:// ghdx.healthdata.org/gbd-results-tool

  2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55. https://doi.org/10.1016/S0140-6736(15)61412-X

  3. Blach S, Collaborators POH. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76. https://doi.org/10.1016/s2468- 1253(16)30181-9

  4. Wall-Martinez HA, Ramirez-Martinez A, Wesolek N, Brabet C, Durand N, Rodriguez-Jimenes GC, et al. Risk assessment of exposure to mycotoxins (aflatoxins and fumonisins) through corn tortilla intake in Veracruz City (Mexico). Food additives & Contaminants. 2019;36(6):929-39. https:// doi.org/10.1080/19440049.2019.1588997

  5. International Agency for Research on Caner. TP53 Mutation Database [Internet]. Lyon: International Agency for Research on Cancer, 2017. Available from: http://www-p53.iarc.fr

  6. Romero-Martínez M, Shamah-Levy T, Vielma-Orozco E, Heredia- Hernández O, Mojica-Cuevas J, Cuevas-Nasu L, et al. National Health and Nutrition Survey 2018-19: methodology and perspectives. Salud Publica Mex. 2019;61(6):917-23. https://doi.org/10.21149/11095

  7. Groopman JD. Environmental health in the biology century: Transitions from population to personalized prevention. Experimental Biology and Medicine. 2019;244(9):728-33. https://doi.org/10.1177/1535370219837903

  8. McCoy LF, Scholl PF, Schleicher RL, Groopman JD, Powers CD, Pfeiffer CM. Analysis of aflatoxin B1-lysine adduct in serum using isotope-dilution liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(16):2203-10. https://doi.org/10.1002/rcm.2045

  9. Smith JW, Kroker-Lobos MF, Lazo M, Rivera-Andrade A, Egner PA, Wedemeyer H, et al. Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. PLoS One. 2017;12(12):e0189255. https://doi. org/10.1371/journal.pone.0189255

  10. Diaz de Leon-Martinez L, Diaz-Barriga F, Barbier O, Ortiz DLG, Ortega- Romero M, Perez-Vazquez F, et al. Evaluation of emerging biomarkers of renal damage and exposure to aflatoxin-B1 in Mexican indigenous women: a pilot study. Environ Sci Pollut Res Int. 2019;26(12):12205-16. https://doi. org/10.1007/s11356-019-04634-z

  11. Chen JG, Egner PA, Ng D, Jacobson LP, Muñoz A, Zhu YR, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prevention Research. 2013;6(10):1038-45. https://doi.org/10.1158/1940-6207.capr-13-0168

  12. Bedard LL, Massey TE. Aflatoxin B1-induced DNA damage and its repair. Cancer Lett. 2006;241(2):174-83. https://doi.org/10.1016/j.canlet. 2005.11.018

  13. Soini Y, Chia SC, Bennett WP, Groopman JD, Wang JS, DeBenedetti VM, et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis. 1996;17(5):1007-12. https://doi.org/10.1093/carcin/17.5.1007

  14. Valdés-Peregrina EN, Sánchez-Hernández BE, Gamboa-Domínguez A. Metabolic syndrome instead of aflatoxin-related TP53 R249S mutation as a hepatocellular carcinoma risk factor. Rev Invest Clin. 2020;72(5):316-22. https://doi.org/10.24875/ric.20000131

  15. Alvarez CS, Ortiz J, Bendfeldt-Avila G, Xie Y, Wang M, Wu D, et al. Analysis of TP53 aflatoxin signature mutation in hepatocellular carcinomas from Guatemala: A cross-sectional study (2016-2017). Health Science Reports. 2020;3(2):e155. https://doi.org/10.1002/hsr2.155

  16. Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, Tang ZY, et al. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology. 2011;140(3):1063-70. https://doi.org/10.1053/j.gastro.2010.11.034




2020     |     www.medigraphic.com